R&D

View All

vedanta
Prometic bags $50M; Vedanta receives $12M; Humira biosimilar deal

Prometic bags USD 50 Million stock sale option to ease a cash crunch Prometic Life Sciences got into an agreement for selling USD 50 million in stock. This gives Prometic a way to escape its current financial pressures. Canada-based Prometic was asked by the FDA to make and validate process changes for Ryplazim, a c...

Find More

Cambrex acquires Avista; Sobi pays $50M; LEO Pharma signs deal; Boston Scientific remunerates

Cambrex takes over Avista in USD 250 Million agreement Cambrex, life sciences company, is taking over Avista Pharma Solutions with a deal of USD 250 million to become a leading contract development and manufacturing organization (CDMO). The agreement includes the early-stage drug development and manufacturing capabi...

Find More

Therapeutics and Celgene to develop therapies; Takeda’s expansion; J&J hopes to limit; Tech Prize for genome sequencing; Endocyte’s late-stage prostate cancer deal

Strategic Immunology Alliance partners Nimbus Therapeutics and Celgene to develop therapies for Autoimmune Disorders A biotechnology company involved in the development of drugs and therapies through computational expertise announced on October 3 that they are entering into a long-term strategic alliance with Celgen...

Find More

Science wins reprieve in US budget deal

Funding for US science agencies will stay flat or even increase over the next several months, under a US$1-trillion spending deal announced on 30 April. The plan devised by Congress, which covers the remainder of the 2017 budget year, avoids the sharp cuts to science proposed by US President Donald Trump. The bigges...

Find More

Ovarian Cancer: The Silent Killers

In United States, Ovarian Cancer has become the leading cause of death in women. Each year approximately 22,280 women are diagnosed with ovarian cancer, and out of those 14,240 die. Women with strong family history of breast cancer or ovarian cancer or who have tested positive for inherited mutation in BRCA1 or BRCA...

Find More